Baird analyst Colleen Kusy lowered the firm’s price target on Karyopharm (KPTI) to $42 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated its pipeline progress.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue